Biotricity Inc.
BTCY Healthcare Medical Devices
Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025. In the quarter to June 2026, revenue grew 10.4%, EPS fell 66.7%, free cash flow grew 235.8% and total debt rose 3.48%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow BTCY
Biotricity Inc. (BTCY) Piotroski F-score
Biotricity Inc.'s Piotroski F-score for fiscal 2026 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 5 | 0.00 |
| FY2025 | 5 | 2.00 |
| FY2024 | 3 | (1.00) |
| FY2023 | 4 | 0.00 |
| FY2022 | 4 | 1.00 |
| FY2021 | 3 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (51.76%) | (206.19%) | Fail | 0 |
| Positive operating cash flow | (719.00k) | (2.38m) | Fail | 0 |
| Rising return on assets | (51.76%) | (206.19%) | Pass | 1 |
| Cash flow above net income | 2.41m | 9.56m | Pass | 1 |
| Falling long-term leverage | 0.14 | 2.27 | Pass | 1 |
| Rising current ratio | 0.16 | 0.22 | Fail | 0 |
| No new shares issued | 27,304,300 | 21,524,900 | Fail | 0 |
| Rising gross margin | 80.94% | 76.61% | Pass | 1 |
| Rising asset turnover | 2.65 | 2.38 | Pass | 1 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| NMTC NeuroOne Medical Technologies Corporation compare | 6 |
| AEMD Aethlon Medical, Inc. compare | 5 |
| BTCY Biotricity Inc. | 5 |
| IRIX IRIDEX Corporation compare | 4 |
| BMRA Biomerica, Inc. compare | 4 |
| PETV PetVivo Holdings, Inc. compare | 3 |
| CTSO Cytosorbents Corporation compare | 3 |
| SINT SINTX TECHNOLOGIES, INC. compare | 2 |
| RBOT Vicarious Surgical Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover